English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Owing to their immunomodulatory effects, antithymocyte globulins and alemtuzumab, commonly referred to as serotherapy (ST), are a common component of allogeneic hematopoietic stem cell transplant (HSCT) conditioning regimens.1, 2 Although the majority of patients receiving ST develop fevers and other adverse events (AE), there are no well-established practice guidelines for the management of ST-related fevers. We hypothesize that few ST-related fevers represent true bloodstream infection (BSI) and propose an evidence-based approach to antibiotic use in this population.

bone marrow transplantation

Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab